Michael Charlton to Immunosuppressive Agents
This is a "connection" page, showing publications Michael Charlton has written about Immunosuppressive Agents.
Connection Strength
2.772
-
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 05; 102(5):727-743.
Score: 0.438
-
Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. Transplantation. 2017 12; 101(12):2873-2882.
Score: 0.426
-
Sirolimus as a calcineurin inhibitor- and renal-sparing agent: all good things come to those who wait versus spare the nephron, spoil the patient. Liver Transpl. 2013 Aug; 19(8):787-9.
Score: 0.315
-
Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012 Sep; 18(9):1029-36.
Score: 0.296
-
Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology. 2011 Jul; 54(1):3-5.
Score: 0.273
-
Antibody-based immunosuppression following liver transplantation: the plot thickens. Am J Transplant. 2010 Mar; 10(3):445-6.
Score: 0.248
-
Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire? Liver Transpl. 2002 Jan; 8(1):47-9.
Score: 0.141
-
Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg. 1999 Jul; 5(4 Suppl 1):S107-14.
Score: 0.119
-
Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review. Liver Transpl. 2013 Dec; 19(12):1311-7.
Score: 0.081
-
How important is acute cellular rejection? Liver Transpl. 2013 Nov; 19 Suppl 2:S9-13.
Score: 0.080
-
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
Score: 0.070
-
Daclizumab induction therapy in liver transplant recipients with renal insufficiency. Aliment Pharmacol Ther. 2010 Sep; 32(6):776-86.
Score: 0.064
-
A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009 Aug; 9(8):1707-13.
Score: 0.059
-
Approach to recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep. 2007 Mar; 9(1):23-30.
Score: 0.051
-
Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl. 2003 Nov; 9(11):S58-62.
Score: 0.040
-
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation. 2017 05; 101(5):956-967.
Score: 0.026
-
Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013 Jul; 19(7):690-700.
Score: 0.019
-
Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks. Br J Dermatol. 2007 Dec; 157(6):1183-8.
Score: 0.013
-
Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation. 2007 Jun 27; 83(12):1639-42.
Score: 0.013